Fact-checked by Grok 2 weeks ago

Colorectal polyp

A colorectal polyp is a small clump of cells that forms on the lining of the colon or , often protruding into the intestinal . Most colorectal polyps are benign and , but certain types can develop into over time if not removed. They affect approximately 20% of adults, with prevalence rising to 40% in those over age 50. Colorectal polyps are classified into several types based on their shape, histology, and potential for malignancy. Neoplastic polyps, such as adenomas (including tubular, villous, and tubulovillous subtypes) and serrated polyps (like sessile serrated lesions), are precancerous and account for about 80% of cases, with roughly 5% already malignant at detection. In contrast, non-neoplastic polyps, including hyperplastic, inflammatory, and juvenile types, are typically harmless and do not progress to cancer. Polyps may appear as pedunculated (stalked, resembling a ) or sessile (flat and broad-based), with the latter often harder to detect. Most individuals with colorectal polyps experience no symptoms, leading to their discovery primarily through routine screening. When present, symptoms may include (manifesting as blood on , in the , or black/tarry stools), changes in bowel habits such as or , , from , or excess in the . The absence of symptoms underscores the importance of screening, such as starting at age 45 for average-risk individuals, which can detect and remove polyps to prevent cancer progression. The exact cause of colorectal polyps remains unclear, but they arise from genetic mutations leading to abnormal in the intestinal lining. Risk factors include advancing age (most common after 45), a personal or family history of polyps or , inflammatory bowel diseases like or , , , heavy use, , and diets low in fiber or high in red/processed meats. Hereditary syndromes, such as (FAP) or Lynch syndrome, significantly elevate risk by causing multiple polyps. Certain populations, including Black individuals in the United States, face higher incidence rates. Treatment typically involves endoscopic removal (polypectomy) during for polyps larger than 5 mm or those with concerning features, which reduces the risk of developing by up to 80%. Larger or sessile polyps may require advanced techniques like endoscopic mucosal resection. Surveillance are recommended based on polyp number, size, and to monitor for recurrence. While prevention is not absolute, lifestyle measures—such as maintaining a healthy weight, exercising regularly, consuming a high-fiber diet rich in fruits and vegetables, limiting , and avoiding —can lower risk.

Overview

Definition and characteristics

A colorectal polyp is defined as an abnormal growth that protrudes from the lining the colon or . These growths are typically benign, though some have the potential to become malignant over time. Polyps can occur anywhere along the , including the proximal colon (, ascending, and transverse segments), distal colon (descending and segments), or , with their location influencing detection and management approaches. Colorectal polyps vary in size, commonly classified as (less than 5 mm in diameter), small (6-9 mm), or large (10 mm or greater), which helps assess . Morphologically, they appear as either pedunculated, with a stalk connecting the growth to the mucosal surface, or sessile, featuring a broad-based attachment without a stalk. In the general , the of colorectal polyps is approximately 25-30% among adults aged 50 years and older, based on screening data, while autopsy studies indicate rates up to 50% by age 70. The understanding of colorectal polyps advanced significantly with the introduction of colonoscopy in the 1960s, enabling direct visualization and removal, which marked a shift from earlier indirect diagnostic methods. Certain polyps, particularly adenomatous ones, play a key role in the adenoma-carcinoma sequence leading to colorectal cancer.

Epidemiology and risk factors

Colorectal polyps are detected in approximately 20-30% of screening colonoscopies in Western countries, with prevalence rates reaching up to 30% in population and autopsy studies among middle-aged and elderly individuals. In contrast, detection rates are lower in Asia and Africa, estimated at 10-15%. Globally, the prevalence of colorectal adenomas, a common type of polyp, is about 23.9% based on systematic reviews of screening data. These geographic variations reflect differences in dietary habits, screening practices, and genetic factors. The incidence of colorectal polyps increases with age, remaining rare under 40 years but rising sharply thereafter, with detection rates of 21-28% in individuals aged 50-59 years, 41-45% in those aged 60-69 years, and 53-58% in those over 70 years. Recent expansions in screening to age 45 have led to increased polyp detection in younger adults, with rates of approximately 25-27% in ages 45-54 as of 2025, aligning with rising early-onset trends. Demographic patterns show higher in males compared to females, with men exhibiting an of approximately 1.68 for distal lesions. Racial and ethnic differences also influence risk, with higher rates observed among Caucasians and relative to or Asian populations; for instance, have a 1.2- to 2-fold increased risk for proximal lesions. Familial clustering is evident, where a family history of polyps elevates individual risk independent of specific syndromes. Modifiable risk factors significantly contribute to polyp development. , particularly with a greater than 30 kg/m², increases the risk by 1.5- to 2-fold, with even higher odds (up to 4.26) for severe ( ≥40). , especially with 20 or more pack-years, approximately doubles the risk, with relative risks around 2.14 for current smokers. Dietary factors play a key role, as high consumption of red and processed meats is associated with a of 1.2-1.5, while low intake exacerbates this vulnerability. include regular , which can reduce polyp risk by about 30%. Recent trends indicate declining rates of advanced neoplasia and in populations with widespread screening programs, attributed to the preventive effect of polypectomy. In the United States, post-2000 screening initiatives contributed to a 20-30% drop in advanced neoplasia rates (as observed in early 2010s studies), though overall incidence declines have slowed to approximately 1% per year as of 2023.

Clinical Presentation

Signs and symptoms

Most colorectal polyps are , especially when small, and are typically discovered incidentally during routine screening for . The vast majority—over 90%—of such polyps are detected in asymptomatic individuals via procedures like . When symptoms arise, they often stem from bleeding or the physical presence of larger polyps. is the most frequent manifestation, appearing as bright red blood on toilet paper or in the stool for distal polyps located in the or , while proximal polyps in the may cause (hidden) bleeding or dark, tarry stools () due to slower blood transit and degradation. Changes in bowel habits, including persistent or lasting more than a week, can occur with sizable polyps that partially obstruct the bowel or produce excess . Chronic, low-grade blood loss from any polyps may lead to , presenting with symptoms such as fatigue, pallor, and . Chronic or acute bleeding from polyp ulceration may result in severe . Rare acute presentations are associated with giant polyps exceeding 4 cm, which can trigger intestinal obstruction or intussusception—a condition where one segment of bowel telescopes into another—resulting in crampy , , , and . Pedunculated polyps, with their stalk-like attachment, may also cause localized if they twist or become torsed. Symptom profiles differ by polyp location: distal lesions more commonly produce noticeable bright red owing to their nearer position to the , whereas proximal polyps are generally less likely to cause overt symptoms and instead contribute to insidious issues like from undetected blood loss.

Complications

Colorectal polyps, particularly adenomatous types, pose a significant of via the adenoma-carcinoma , where benign growths progressively accumulate genetic alterations leading to invasive cancer. This process typically spans 10 to 25 years from adenoma inception to cancer development, though high- adenomas—such as those with villous , high-grade , or size greater than 1 cm—may progress within 5 to 10 years. The malignancy escalates with polyp size: approximately 1% for lesions under 1 cm, 10% for those 1 to 2 cm, and up to 50% for polyps exceeding 2 cm in diameter. Non-malignant complications from untreated polyps are less common but can be serious. Chronic or acute from polyp ulceration may result in severe . Intestinal obstruction occurs rarely, though it is more frequent in juvenile polyps or polyposis syndromes due to polyp bulk or multiplicity. during polyp growth is extremely rare, typically limited to isolated case reports involving large or inflammatory lesions. Sessile serrated lesions follow a distinct serrated neoplastic pathway to cancer, often driven by early BRAF mutations, which promote CpG island methylator phenotype progression and . These polyps contribute to 15-30% of colorectal cancers and carry a slower but insidious if undetected. Undetected colorectal polyps account for over 95% of colorectal cancers, underscoring their role in preventable mortality when screening and removal are neglected.

Pathology

Histological structure

Colorectal polyps arise from the epithelial lining of the colonic mucosa, forming exophytic or sessile projections that can be neoplastic or non-neoplastic in nature. Neoplastic polyps, primarily adenomas, exhibit glandular architecture derived from dysplastic colonic epithelium, while non-neoplastic polyps display reactive or disorganized mucosal components without dysplasia. Microscopically, these lesions are evaluated for architectural patterns and cellular atypia to distinguish their potential behavior. In adenomatous polyps, the hallmark is a proliferation of dysplastic glands resembling colonic mucosa but with aberrant growth. Tubular adenomas feature closely packed, branching tubular glands with round to oval lumina, often showing a pedunculated or sessile configuration. Villous adenomas display elongated, finger-like villous fronds with fibrovascular cores lined by tall columnar cells, whereas tubulovillous adenomas combine both patterns, with 25-75% villous component. Dysplasia is graded using a two-tiered system: low-grade dysplasia involves mild architectural distortion, such as pseudostratification and loss of nuclear polarity, with cytological features like hyperchromasia and small nucleoli; high-grade dysplasia shows marked atypia, including complex glandular crowding, cribriforming, increased nuclear-to-cytoplasmic ratios, and prominent nucleoli, indicating a higher risk of progression. Non-neoplastic polyps lack dysplastic changes and include hyperplastic, inflammatory, and hamartomatous types. Hyperplastic polyps demonstrate a serrated glandular architecture with saw-tooth-like crypts confined to the upper half of the , featuring microvesicular in cells and no basal crypt branching. Inflammatory pseudopolyps consist of inflamed and eroded surface mucosa with expanded containing mixed inflammatory infiltrates, crypt abscesses, and featuring dilated thin-walled vessels and . Hamartomatous polyps, such as juvenile polyps, are characterized by disorganized, cystically dilated glands filled with and inflammatory debris, embedded in edematous stroma rich in lymphocytes and plasma cells. Histological diagnosis relies primarily on hematoxylin and eosin (H&E) , which highlights epithelial architecture, glandular patterns, and cytological for routine evaluation. Special stains, such as Ki-67 , assess proliferative activity by revealing nuclear in epithelial cells, often showing an expanded basal proliferative zone in adenomas or irregular foci in serrated lesions to aid in distinguishing subtle .

Genetic and molecular basis

The development of colorectal polyps involves a series of genetic mutations that drive initiation and progression, particularly in sporadic adenomas. Inactivating mutations in the gene occur in approximately 80% of sporadic adenomas and represent an early initiating event by disrupting the , leading to uncontrolled . Progression to advanced adenomas is often marked by activating mutations in the in 30-50% of cases, which enhance downstream signaling in the MAPK pathway and promote growth. In late-stage lesions approaching carcinoma, loss-of-function mutations in the TP53 tumor suppressor gene accumulate, impairing and , further destabilizing the genome. Two primary molecular pathways underlie polyp formation and : the classic adenoma-carcinoma driven by chromosomal (CIN) and the serrated neoplasia pathway characterized by epigenetic alterations. The CIN pathway, responsible for most conventional adenomas, features progressive accumulation of chromosomal aberrations, including and , often initiated by APC inactivation and culminating in widespread genomic . In contrast, the serrated pathway predominates in sessile serrated lesions and involves the CpG island methylator phenotype (CIMP), where hypermethylation silences tumor suppressor genes, combined with the BRAF V600E mutation in about 80% of sessile serrated polyps, activating the MAPK pathway independently of . This pathway frequently leads to through MLH1 promoter methylation. Hereditary syndromes account for a subset of polyps with distinct genetic bases, predisposing individuals to polyposis through mutations. Familial adenomatous polyposis (FAP) arises from APC mutations, resulting in hundreds to thousands of adenomas typically by the second decade of life, with near-certain progression to if untreated. Lynch syndrome, caused by defects in genes such as MLH1 or MSH2, confers a 70-80% lifetime risk of , often through fewer but rapidly progressing adenomas exhibiting . Peutz-Jeghers syndrome stems from mutations, leading to hamartomatous polyps throughout the accompanied by mucocutaneous melanin pigmentation. Juvenile polyposis syndrome involves mutations in SMAD4 or BMPR1A, which disrupt TGF-β signaling and cause multiple (typically 5 or more, but ranging from a few to hundreds) hamartomatous polyps primarily in the colorectum, increasing cancer risk over time. Recent advances highlight the interplay of environmental factors and emerging detection technologies in polyp pathogenesis. By 2025, studies have elucidated the gut microbiome's role in promoting serrated lesion formation, with dysbiotic communities enriched in and certain species fostering and BRAF activation in susceptible individuals. Additionally, liquid biopsy techniques detecting (ctDNA) have shown promise for non-invasive polyp surveillance, with reported sensitivities for advanced adenomas around 23% in recent multimodal assays through or , though specificity remains a challenge for early lesions.

Classification

Major types

Colorectal polyps are broadly classified into neoplastic and non-neoplastic categories based on their histological features and potential for . Neoplastic polyps, which are precancerous, include adenomas and serrated lesions, while non-neoplastic polyps lack this malignant potential and arise from various benign processes. Adenomas represent the most common neoplastic polyps and are subclassified by into tubular, villous, and tubulovillous types. Tubular adenomas account for approximately 70% of cases, characterized by simple glandular structures with low malignant potential in small lesions but increasing risk with size and villous components. Villous adenomas comprise 5-15% and feature elongated, finger-like projections, conferring the highest risk of progression to among adenomas. Tubulovillous adenomas make up 20-25%, blending features of both and exhibiting intermediate risk. Serrated polyps form another key neoplastic subgroup, distinguished by a saw-tooth glandular and varying cancer risk. Hyperplastic polyps, the most frequent serrated type, are typically small, distal, and carry a very low risk of (<1%). In contrast, sessile serrated lesions (also called sessile serrated adenomas or polyps) are larger, right-sided, and have a higher progression risk of 5-15% due to their precursor role in the serrated neoplasia pathway. Traditional serrated adenomas, rarer and often left-sided, show mixed serrated and adenomatous features with elevated malignant potential. Non-neoplastic polyps include hamartomatous and inflammatory variants, which do not typically progress to cancer. Hamartomatous polyps, such as (often solitary in children) and (multiple and associated with a hereditary syndrome), consist of disorganized normal tissue elements like cystic glands and smooth muscle. Inflammatory pseudopolyps arise in , representing islands of regenerating mucosa amid ulceration rather than true neoplasms. Rare non-neoplastic types encompass lipomatous polyps, composed of adipose tissue and usually asymptomatic, and lymphoid polyps, which are nodular aggregates of immune cells. Metaplastic polyps, sometimes termed mucosal prolapse polyps, feature fibromuscular changes due to mechanical stress and are not true polyps but reactive proliferations. The World Health Organization's 2019 classification, which remains the standard as of 2025, refined polyp taxonomy, particularly elevating sessile serrated lesions as a distinct entity from hyperplastic polyps owing to their differing molecular profiles and cancer risks, aiding in targeted surveillance. This update underscores the role of BRAF mutations and CpG island methylator phenotype in serrated pathways, distinct from the APC-driven adenoma-carcinoma sequence.

Comparison of histological features

Colorectal polyps exhibit diverse histological features that distinguish their types and inform clinical risk assessment. Non-neoplastic polyps, including hyperplastic, inflammatory, and hamartomatous variants, generally lack dysplasia and show benign architectural patterns, whereas neoplastic polyps such as conventional and certain serrated lesions demonstrate cytological atypia and structural abnormalities indicative of malignant potential. These differences are critical for determining progression risk, with neoplastic types progressing through the or serrated pathway to . Key histological differentiators center on the presence of dysplasia and architectural complexity. Neoplastic polyps like feature dysplastic epithelium—ranging from low-grade in tubular forms to high-grade in villous subtypes—arranged in glandular or frond-like patterns, conferring substantial malignant potential that escalates with villous components or size exceeding 1 cm (approximately 10-20% risk of harboring invasive cancer). In contrast, non-neoplastic polyps such as display uniform serration without dysplasia, while inflammatory polyps exhibit stromal inflammation and surface erosion, both with negligible progression risk (<1%). Hamartomatous polyps, characterized by malformed but mature tissues, also lack dysplasia but may signal syndromic associations elevating overall cancer susceptibility. Among serrated polyps, stand out with boot-shaped crypts and lateral growth, bridging non-neoplastic and neoplastic categories due to their potential for dysplasia development. Prevalence among endoscopically detected polyps reflects these distinctions: conventional adenomas comprise 60-70%, hyperplastic polyps 20-30%, inflammatory polyps around 10-20% in inflammatory bowel disease contexts, hamartomatous polyps less than 1%, and serrated lesions (including sessile subtypes) approximately 20-30% overall, with traditional serrated adenomas rarer at 1-5%. Diagnostic challenges are prominent in borderline cases, particularly differentiating hyperplastic polyps from sessile serrated lesions, where subtle features like crypt base serration or dilation may be overlooked in superficial sections, leading to interobserver disagreement rates of 20-40%; exhaustive sectioning and immunohistochemical aids are often necessary for accurate classification. Multidisciplinary review is recommended for complex or diagnostically challenging polyps, prioritizing histological confirmation to guide risk stratification without over-resection.
Polyp TypeHistological FeaturesMalignancy RiskLocation PreferenceApproximate Prevalence
Hyperplastic polypSerrated crypts with regular architecture, no Low (<1%)Distal colon/rectum20-30%
Sessile serrated lesionSerrated architecture with crypt dilation, horizontal extension, possible low-grade Intermediate (5-15% if ≥1 cm or dysplastic)Proximal colon3-9%
Tubular adenomaBranched tubular glands with low- to high-grade Variable (1% if <1 cm; 10-20% if >1 cm)Throughout (distal for small)50-60%
Villous adenomaLeaf-like villous projections with high-grade High (20-40%)Distal colon5-10%
Hamartomatous polyp (e.g., juvenile)Disorganized admixture of glands, stroma, and cysts; no Low (<1%)Variable<1%
Inflammatory polypSurface erosion with inflammatory granulation tissue and fibrosis; no Very low (<1%)Areas of inflammation (e.g., IBD)10-20% in IBD contexts
Molecular markers, such as BRAF V600E mutations prevalent in sessile serrated lesions, can support histological differentiation in ambiguous cases.

Diagnosis

Screening and detection methods

Screening for colorectal polyps is a cornerstone of early detection strategies aimed at preventing colorectal cancer, focusing on asymptomatic individuals at average risk. The United States Preventive Services Task Force (USPSTF) recommends initiating screening at age 45 years and continuing through age 75 years, with a grade A recommendation for adults aged 50 to 75 and grade B for those aged 45 to 49, based on evidence of substantial net benefit in reducing colorectal cancer incidence and mortality. For adults aged 76 to 85 years, screening should be selectively offered based on individual health status and prior screening history. These guidelines, established in 2021 and unchanged as of 2025, endorse multiple modalities, including colonoscopy every 10 years or annual fecal immunochemical testing (FIT), with the choice depending on patient preferences, access, and local resources. Non-invasive screening methods prioritize accessibility and patient compliance by detecting markers of potential neoplasia without direct visualization. FIT, which identifies hidden hemoglobin in stool samples, is recommended annually and demonstrates high sensitivity for colorectal cancer (74% to 92%) but lower sensitivity for advanced adenomas (approximately 24%), making it effective for triaging patients who require follow-up colonoscopy. Multitarget stool DNA testing, such as , combines DNA biomarkers and FIT, achieving 92.3% sensitivity for colorectal cancer and 42.4% for advanced precancerous lesions (including adenomas ≥1 cm), though it has a higher false-positive rate (13%) compared to FIT alone (5%). CT colonography, also known as virtual colonoscopy, offers 90% per-patient sensitivity for adenomas or cancers ≥10 mm, with the advantage of imaging the entire colon non-invasively every five years, though it requires bowel preparation and may detect extracolonic findings necessitating additional evaluation. Invasive methods provide direct visualization and the opportunity for immediate intervention. Colonoscopy remains the gold standard, with per-patient sensitivity exceeding 95% for large polyps (≥10 mm) and the capability to resect detected lesions during the procedure, recommended at 10-year intervals for average-risk individuals. Flexible sigmoidoscopy, which examines the distal colon, detects approximately 60% to 70% of advanced neoplasms (primarily in the rectosigmoid) and is performed every five to 10 years, often combined with FIT for comprehensive coverage. Emerging technologies aim to enhance detection rates and reduce procedural burdens. AI-assisted capsule endoscopy, involving ingestible devices that capture colonic images analyzed by machine learning algorithms, has shown promising results in recent trials (2023–2025), with sensitivity rates around 84% to 92% for polyps ≥6 mm, potentially improving polyp yield and diagnostic accuracy while minimizing reading times. Blood-based tests, such as the FDA-approved Shield test (multitarget cell-free DNA assay) introduced in 2024, offer another non-invasive option for average-risk adults, with 83% sensitivity for colorectal cancer and 13% for advanced adenomas, recommended every three years, though with lower detection of precancerous lesions compared to stool-based methods. Despite these advances, disparities in screening access and uptake persist, particularly among racial and ethnic minorities. For instance, as of 2023, colorectal cancer screening rates are lower among Hispanic (approximately 53%), Black (66%), and many Asian subgroups (50-60%) adults compared to non-Hispanic Whites (70-80%), attributed to barriers such as limited healthcare access, language challenges, and socioeconomic factors, which exacerbate inequities in early polyp detection.

Endoscopic evaluation and classification

Endoscopic evaluation of colorectal polyps is primarily performed via colonoscopy, which allows direct visualization and characterization of lesions within the colon and rectum. Adequate bowel preparation is essential, typically involving a split-dose regimen of oral polyethylene glycol-based laxatives administered the day before and morning of the procedure to ensure clear visualization of the mucosa. Conscious sedation, often with a combination of midazolam and fentanyl, is commonly used to enhance patient comfort during the procedure, which lasts 20-30 minutes on average. The colonoscope, a flexible tube with a camera, is advanced from the anus through the rectum, sigmoid, descending, transverse, ascending colon, and into the cecum, with air or carbon dioxide insufflation to distend the lumen for optimal inspection. During colonoscopy, polyps are characterized and often removed via polypectomy techniques tailored to their morphology. Pedunculated polyps, which have a stalk, are typically resected using hot snare polypectomy, where an electrocautery snare is looped around the stalk and current is applied to cut and coagulate, reducing bleeding risk for lesions larger than 10 mm. Sessile polyps, which lack a stalk and are flat-based, often require endoscopic mucosal resection (EMR), involving submucosal injection of saline or a lifting agent to elevate the lesion, followed by en bloc or piecemeal snare resection to ensure complete removal while minimizing perforation risk. These methods allow for both diagnostic sampling and therapeutic intervention in a single procedure. Classification systems facilitate real-time assessment of polyp morphology and histology during endoscopy. The Paris classification describes superficial neoplastic lesions based on endoscopic appearance: type 0-Ip denotes pedunculated polyps with a narrow stalk, while 0-Is indicates sessile polyps with a broad base; flat lesions are categorized as 0-IIa (slightly elevated), 0-IIb (non-protruding), or 0-IIc (slightly depressed), aiding in risk stratification for submucosal invasion. The Narrow-band Imaging International Colorectal Endoscopic (NICE) classification, used with narrow-band imaging, differentiates polyp types by color, vascular pattern, and surface structure: type 1 (hyperplastic-like) features a colorless or brownish hue with straight, dark vessels and indistinct surface patterns; type 2 (adenoma-like) shows a brownish color with tubular or branched vessels surrounding white structures; and type 3 (deep submucosal invasive cancer-like) exhibits disrupted vessels and amorphous surfaces. This system enables optical diagnosis with high accuracy for diminutive polyps. Advanced imaging enhances polyp characterization beyond white-light endoscopy. Narrow-band imaging (NBI) filters light to emphasize vascular and mucosal patterns, improving adenoma detection; meta-analyses report sensitivity exceeding 90% and negative predictive value over 90% for high-confidence predictions of histology in small polyps. Chromoendoscopy involves spraying dyes such as indigo carmine or methylene blue onto the mucosa to highlight pit patterns and borders, increasing adenoma detection rates by accentuating subtle lesions, particularly in high-risk patients. These techniques support "resect-and-discard" strategies for low-risk polyps when optical diagnosis aligns with histopathology. Histopathological confirmation follows endoscopic sampling, with protocols ensuring adequate tissue for analysis. For large or sessile lesions undergoing EMR, biopsies are often taken from the resection margins in a 4-quadrant fashion to assess completeness and rule out residual neoplasia. Resected polyps or biopsy specimens are fixed in formalin, processed, and examined microscopically for features like dysplasia or invasion. Turnaround time for histopathology reports typically ranges from 3 to 7 days, though complex cases may extend to 1-2 weeks, guiding subsequent management decisions.

Management

Treatment approaches

Treatment of colorectal polyps primarily involves endoscopic removal to prevent progression to malignancy, with techniques selected based on polyp size, histology, location, and accessibility. Polypectomy is the standard approach for most polyps encountered during colonoscopy, aiming for complete resection with clear margins to minimize recurrence. The choice of method balances efficacy, safety, and the endoscopist's expertise, guided by international society recommendations.35122-2/fulltext) For diminutive polyps (≤5 mm), cold snare polypectomy (CSP) is recommended, incorporating a 1-2 mm margin of normal tissue to ensure complete removal, achieving high success rates with minimal tissue distortion for histological assessment. This technique avoids electrocautery, reducing the risk of thermal injury while effectively resecting small lesions in a single pass. For slightly larger polyps (6-9 mm), either cold or hot snare polypectomy may be used, with cold snare preferred in scenarios prioritizing simplicity and lower complication risk. Larger sessile or flat polyps (≥10 mm) typically require more advanced endoscopic techniques such as endoscopic mucosal resection (EMR), which involves submucosal injection of fluid to lift the lesion before snare excision, enabling en bloc or piecemeal removal. EMR achieves complete resection in approximately 89% of cases in a single session, with local recurrence rates as low as 1-2% when adequate margins are obtained and sites are inspected post-procedure.00274-5/fulltext) For non-pedunculated polyps with suspected early invasive cancer or requiring en bloc resection for precise staging, endoscopic submucosal dissection (ESD) is employed, offering curative rates of 86-90% through meticulous dissection of the submucosa. ESD is particularly advantageous in the right colon for large lesions but demands specialized training due to its technical complexity. In cases of giant polyps (>20-30 mm) that are unresectable endoscopically due to size, location, or , or those exhibiting deep submucosal on imaging or , surgical resection via or transanal excision is indicated to achieve curative intent. For residual or recurrent polyp tissue post-polypectomy, ablative methods like (APC) can be applied to achieve and eradicate remnants, particularly in piecemeal resections. Treatment strategies vary by polyp type: low-risk hyperplastic polyps, especially small distal ones, may be managed conservatively if confirmed histologically benign with negligible malignant potential, though removal is often performed to avoid diagnostic uncertainty. In contrast, adenomatous polyps, including those with high-grade , warrant aggressive endoscopic removal regardless of size, as they harbor significant neoplastic risk and complete excision is essential for . , such as distinguishing adenomas from hyperplastic lesions, informs this tailored approach. Overall outcomes for polypectomy are favorable, with bleeding occurring in 0.5-1.5% of cases—most commonly immediate and manageable endoscopically—and perforation rates ranging from 0.1-0.6 per 1,000 procedures, higher with larger lesions or right-sided resections. Recent advancements as of 2025 incorporate ()-assisted colonoscopy, which enhances polyp detection and characterization, reducing adenoma miss rates by up to 20-30% and incomplete resection rates to below 10% through real-time guidance during polypectomy. Systems like ENDOANGEL have demonstrated superior efficacy in improving complete resection metrics compared to standard techniques.

Surveillance and follow-up

Surveillance after polypectomy for colorectal polyps is guided by risk stratification to detect metachronous lesions or recurrence, with recommendations primarily from the U.S. Multi-Society Task Force (USMSTF) on . Low-risk findings, such as no polyps or 1-2 tubular adenomas smaller than 10 mm, warrant a repeat in 7-10 years, aligning with average-risk screening intervals. Intermediate-risk cases, including 3-4 tubular adenomas smaller than 10 mm or a sessile serrated smaller than 10 mm without , recommend surveillance in 3-5 years. High-risk features—defined by polyp size ≥10 mm, villous , high-grade , or 5-10 adenomas—necessitate closer monitoring with in 3 years, while more than 10 adenomas at baseline may require evaluation within 1 year to assess for incomplete removal or missed lesions. The report plays a pivotal role in tailoring these protocols, as it determines risk category based on adenoma number, size, , and grade, ensuring personalized follow-up to balance detection of advanced neoplasia with procedural burden. Repeat remains the cornerstone method for , allowing direct and resection of new polyps, though non-invasive options like fecal immunochemical testing (FIT) may or substitute in average-risk patients post-polypectomy when is contraindicated or declined, particularly for extending intervals in low-risk scenarios.05458-1/fulltext) For patients with hereditary syndromes such as (), lifetime surveillance is essential due to near-certain polyp development, with guidelines recommending annual or biennial starting in the early teens (ages 10-15) for classic FAP to monitor polyp burden and timing for prophylactic colectomy.30054-7/fulltext) Adherence to these surveillance recommendations varies, with studies reporting rates around 50-60%, influenced by barriers including access to care, patient anxiety, sedation concerns, and socioeconomic factors that contribute to both under- and over-utilization of procedures.

Prevention

Lifestyle and dietary strategies

Adopting a diet rich in is associated with a reduced of developing colorectal polyps. Meta-analyses of studies indicate that high intake, typically exceeding 25 grams per day, is linked to a 20-30% lower of colorectal adenomas compared to low intake, with a summary (SRR) of approximately 0.72 for the highest versus lowest categories.01586-2/fulltext) This protective effect is attributed to mechanisms such as the fermentation of by , producing like butyrate, which inhibits and promotes in colonic epithelial cells, thereby preventing polyp formation. The World Cancer Research Fund (WCRF) International's 2025 report on dietary and lifestyle patterns reinforces these findings, recommending fiber-rich foods as part of a broader strategy for prevention, noting consistent associations across large-scale studies. Increased consumption of fruits and vegetables also contributes to polyp risk reduction. Cohort studies suggest that of at least five servings per day is associated with a (RR) of about 0.8 for colorectal adenomas, particularly for fruits, due to their and anti-inflammatory properties that mitigate in the colonic mucosa. In contrast, limiting to less than 500 grams per week (cooked weight) is advised, as higher consumption is linked to elevated polyp risk through mechanisms involving iron and heterocyclic amines that promote DNA damage and ; meta-analyses show that adhering to this limit can reduce precursor risks by up to 24%. Regular and are key lifestyle interventions. Engaging in at least 150 minutes of moderate-intensity exercise per week, such as brisk walking, is associated with approximately a 25% reduction in colorectal polyp incidence, as evidenced by meta-analyses of observational studies showing dose-dependent benefits on insulin sensitivity and gut . For , achieving a 5-10% body in individuals correlates with a 15-46% decrease in incidence, likely by lowering and levels that foster polyp development. Moderating alcohol and quitting smoking further support prevention. Limiting alcohol to less than one per day (equivalent to under seven drinks weekly) appears protective against adenomas, with studies showing no increased risk and potential modest benefits from low intake via effects, though higher consumption elevates risk. significantly lowers polyp risk over time; former smokers who quit for 10 or more years experience roughly a 50% reduction in serrated polyp odds compared to current smokers, as tobacco carcinogens like nitrosamines diminish in the colonic environment post-cessation.30149-1/fulltext) These strategies, when combined, amplify benefits, as highlighted in the WCRF's comprehensive of meta-analyses confirming their role in reducing polyp formation through synergistic effects on gut and .

Screening guidelines and chemoprevention

Screening guidelines for colorectal polyps emphasize early detection to prevent progression to cancer, with major organizations recommending initiation at age 45 for average-risk individuals. The (ACS) 2023 guidelines advocate starting multitiered screening options at age 45, including annual fecal immunochemical testing (FIT), guaiac-based fecal occult blood testing (gFOBT), multitarget stool DNA testing every three years, every 10 years, computed tomography colonography every five years, or every five years, tailored to patient preferences and access. In , 2024 guidelines from the Initiative on Colorectal Cancer promote organized, population-based FIT screening programs starting at age 50 in most countries, which have achieved 20-40% reductions in incidence in implemented nations through high participation and early polyp detection. Chemoprevention strategies target pharmacological agents to inhibit polyp formation or progression, particularly in high-risk groups. Low-dose aspirin (75-100 mg daily) has demonstrated a 50% risk reduction for colorectal neoplasia in individuals with Lynch syndrome, as shown in the 2025 CaPP3 trial, building on earlier CAPP2 findings of 20-30% reduction with higher doses (600 mg) over long-term follow-up. For select high-risk patients, such as those with Lynch syndrome or elevated cardiovascular risk, the U.S. Preventive Services Task Force (USPSTF) 2022 statement notes insufficient evidence for broad aspirin use in prevention but supports individualized consideration based on bleeding risks. Nonsteroidal anti-inflammatory drugs (NSAIDs) like (150 mg twice daily) reduce polyp burden by approximately 40% in (), with sustained effects on polyp number and size in rectal segments post-surgery. Emerging agents show promise but require further validation. Observational studies in diabetic patients indicate metformin use is associated with 15-25% lower risk of recurrence, independent of glycemic control, through mechanisms like AMPK activation inhibiting . supplementation (up to 4000 /day) has mixed evidence; the VITAL found no significant reduction in adenoma incidence at 2000 /day over five years, though subgroup analyses suggest potential benefits in deficient populations. Personalized prevention is advancing with polygenic risk scores (PRS) in 2025 research, which identify 10-20% of individuals as high-risk for colorectal neoplasia, enabling targeted screening intensification beyond family history alone and improving risk stratification in diverse populations. These approaches synergize with modifications to enhance overall polyp prevention efficacy.

References

  1. [1]
    Colon polyps - Symptoms and causes - Mayo Clinic
    Sep 24, 2025 · A colon polyp is a small clump of cells that forms on the lining of the colon. Most colon polyps are harmless. But over time, some colon polyps ...Diagnosis and treatment · Large polyp · Small polyps
  2. [2]
    Colon Polyps: Symptoms, Causes, Types & Removal
    Colon polyps are growths that form on the inside of your colon. They're usually benign, but some types can become cancerous.Adenomas · Tubular Adenomas · Serrated Polyps · Endoscopic Mucosal Resection
  3. [3]
    Symptoms & Causes of Colon Polyps - NIDDK
    Learn the symptoms and causes of colon polyps. Most people with colon polyps don't have symptoms, but rectal bleeding and bloody stools may occur.
  4. [4]
    Definition & Facts for Colon Polyps - NIDDK
    Colon polyps are growths on the lining of your colon and rectum. You can have more than one colon polyp. Are colon polyps cancerous? Colon and rectal cancer— ...
  5. [5]
    Colon Polyps - StatPearls - NCBI Bookshelf - NIH
    Colon polyps are protrusions occurring in the colon lumen most commonly sporadic or as part of other syndromes. Polyps are classified as diminutive if 5 mm ...
  6. [6]
    Colorectal polyps and polyposis syndromes - PMC - PubMed Central
    A polyp is defined as any mass protruding into the lumen of a hollow viscus. Colorectal polyps may be classified by their macroscopic appearance as sessile ( ...<|control11|><|separator|>
  7. [7]
    A retrospective study of patients with colorectal polyps - PMC - NIH
    Colonoscopic screening studies in asymptomatic people suggest that the prevalence of adenomas is about 25 to 30 percent at age 50 (12–14) and autopsy studies ...
  8. [8]
    History of colonoscopy and technological advances: a narrative review
    Apr 20, 2023 · Colonoscopy first commenced in 1960s stemming from innovations in upper endoscopy (4). Gradual innovations into imaging technology, guideline developments, ...
  9. [9]
    Pathways of Colorectal Carcinogenesis - PMC - NIH
    Adenoma–Carcinoma Sequence. Most colorectal tumors arise from pre-cancerous polyps that are broadly categorized as either traditional tubular adenomas or ...
  10. [10]
    Colonic Polyps: Practice Essentials, Background, Pathophysiology
    Mar 9, 2020 · Population and autopsy studies suggest that about 30% of middle-aged or elderly individuals have colonic polyps. In comparison, the incidence of ...Practice Essentials · Pathophysiology · Etiology · Epidemiology
  11. [11]
    [PDF] Original Article A study of detection rate and colonoscopic ...
    Jul 30, 2016 · The estimated incidence rate of colonic polyps is 30% in Western countries and 10%-15% in Asian and African countries [1, 2].
  12. [12]
    Global Prevalence of Colorectal Neoplasia: A Systematic Review ...
    We found the overall prevalence rates of any colorectal adenoma, advanced adenoma, and cancer to be 23.9%, 4.6%, and 0.4%, respectively.Systematic Reviews And... · Supplementary Material · Supplementary References<|control11|><|separator|>
  13. [13]
    INFLUENCE OF PATIENT AGE AND COLORECTAL POLYP SIZE ...
    Polyp size is associated with presence of adenomas, a villous component, and dysplasia, whereas patient age is more frequently associated with sessile polyps ...
  14. [14]
    Factors that Increase Risk of Colon Polyps - PMC - NIH
    The prevalence of colorectal neoplasms appears to be higher in Japanese and Korean populations than in other Asian populations.Race Influences Risk · Smoking · Gender And Body Size
  15. [15]
    [PDF] Risk Factors for Colorectal Polyps and Cancer - BINASSS
    NONMODIFIABLE RISK FACTORS. Nonmodifiable risk factors for adenomatous polyps include age, sex, race/ethnicity, genetic polyposis syndromes, and family history.
  16. [16]
  17. [17]
    Colonoscopic Polypectomy and Long-Term Prevention of Colorectal ...
    Feb 23, 2012 · We previously reported that colonoscopic polypectomy in the National Polyp Study (NPS) cohort reduced the incidence of colorectal cancer. An ...
  18. [18]
    Polyps of the Colon and Rectum - Digestive Disorders - MSD Manuals
    A large polyp may cause cramps, abdominal pain, obstruction, or intussusception (one segment of the intestine slides into another, much like the parts of a ...Diagnosis Of Colorectal... · Small-Intestine Cancer · Rare Types Of...
  19. [19]
    Cause, Epidemiology, and Histology of Polyps and Pathways ... - NIH
    Contemporary estimates of adenoma prevalence are based on studies of colonoscopy, which generally report adenomas in 20% to 53% of individuals 50 years or older ...
  20. [20]
    Clinical predictors of colorectal polyps and carcinoma in a low ... - NIH
    Mar 14, 2008 · The risk of developing adenocarcinoma is 1% in adenomas of up to 1 cm in size, 10% in adenomas from 1 cm to 2 cm in diameter and 50% in those ...
  21. [21]
    Colorectal polyposis and inherited colorectal cancer syndromes - PMC
    They are most commonly peri-ampullary and develop around 15 years after colorectal adenomas. The duodenal adenoma burden is scored using the Spigelman staging ...Introduction · Table 3 · Familial Adenomatous...Missing: timeline | Show results with:timeline
  22. [22]
    Unusual complication in patient with Gardner's syndrome ...
    Sep 26, 2018 · We report a complicated GS case that we managed for multiple intestinal perforation and massive gastrointestinal bleeding.
  23. [23]
    BRAF mutation as a potential marker to identify the proximal colon ...
    BRAF(V600E) mutation is a specific molecular feature and driver of the serrated pathway. Serrated polyps are considered to differ not only morphologically, but ...
  24. [24]
    Serrated pathway in colorectal carcinogenesis - PMC - NIH
    It has been estimated that HPs take 7.5 years to progress to serrated adenoma[33]. However, only a tiny percentage of hyperplastic polyps will progress to ...Introduction · Morphological Aspects Of... · Putative Genetic Pathways In...Missing: timeline | Show results with:timeline
  25. [25]
    Clinical evidence for the adenoma-carcinoma sequence ... - PubMed
    Interruption of the adenoma-carcinoma sequence by resecting adenomatous polyps is a powerful method of secondary prevention of colorectal cancer. Colonoscopy ...
  26. [26]
    Colorectal Polyps - PMC - NIH
    Colorectal polyps are classified histologically as neoplastic or non-neoplastic (Table 1). The majority of polyps are small, non-neoplastic lesions that are ...
  27. [27]
    Polyp overview - Pathology Outlines
    Jul 31, 2020 · Definition / general. A polyp is an exophytic or sessile lesion distinct from the mucosal surface and may be neoplastic or nonneoplastic.
  28. [28]
    Tubular adenoma - Colon - Pathology Outlines
    Aug 15, 2022 · Neoplastic colon polyp with at least low grade dysplasia. ... (histologic) description | Microscopic (histologic) images | Positive stains ...
  29. [29]
    Tubulovillous / villous adenoma - Pathology Outlines
    Jun 21, 2022 · Villous or tubulovillous histology is associated with increased risk of colorectal neoplasia: 16.8% versus 9.7% compared with tubular adenomas ...<|separator|>
  30. [30]
    The histomorphological and molecular landscape of colorectal ... - NIH
    Colorectal serrated lesions and polyps are characterized by a serrated (sawtooth or stellate) architecture of the epithelium and gland. Serrated polyp is like ...
  31. [31]
    Hyperplastic polyp - Pathology Outlines
    Nov 18, 2021 · Colon - Hyperplastic polyp is a very common type of polyp in the colon and rectum associated with no significant risk of malignant ...
  32. [32]
    Inflammatory polyp - Pathology Outlines
    Apr 17, 2025 · Nonneoplastic colon polyp composed of inflamed mucosa; Typically shows surface erosion with surrounding granulation tissue and epithelial ...
  33. [33]
    Juvenile (retention) polyp - Pathology Outlines
    Nov 17, 2021 · Most common type of pediatric intestinal polyp, with prominent, cystically dilated glands and inflammatory stroma (> 90% of childhood colon ...
  34. [34]
    An update on the morphology and molecular pathology of serrated ...
    This review will summarize our current understanding of serrated polyps and associated carcinomas with a focus on diagnostic criteria, morphologic ...
  35. [35]
    Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) - NCBI
    Jun 8, 2024 · Identifying patients with Lynch syndrome is important because their lifetime risk of colorectal cancer is 80%, and up to 60% for endometrial ...
  36. [36]
    KRAS and TP53 Mutations in Colorectal Carcinoma - PMC - NIH
    [6] Thus, somatic KRAS mutation is an early event in colorectal carcinogenesis, predominantly occurring during the transformation of a small to intermediate ...
  37. [37]
    p53 in colorectal cancer: from a master player to a privileged therapy ...
    Jun 19, 2025 · This article provides a comprehensive review of the advancements in understanding the relationship between the TP53 gene and CRC, and discusses current ...
  38. [38]
    THE CHROMOSOMAL INSTABILITY PATHWAY IN COLON CANCER
    Chromosomal instability is observed in benign adenomas and increases in tandem with tumor progression.
  39. [39]
    The histologic features, molecular features, detection and ... - Frontiers
    Mar 6, 2024 · The BRAF V600E mutation, in conjunction with CIMP-H, is recognized as a molecular characteristic within the colorectal sessile serrated ...
  40. [40]
    Familial Adenomatous Polyposis - StatPearls - NCBI Bookshelf - NIH
    May 5, 2024 · FAP is primarily caused by germline mutations in the APC gene, located on chromosome 5q21-22. FAP is characterized by the development of ...Introduction · Etiology · Evaluation · Treatment / Management
  41. [41]
    Peutz-Jeghers Syndrome - GeneReviews® - NCBI Bookshelf
    Feb 23, 2001 · Of nine individuals with an unknown hamartomatous polyposis, pathogenic variants were seen in STK11 (4 individuals), BMPR1A (2), and SMAD4 (1).
  42. [42]
    Juvenile Polyposis Syndrome - GeneReviews® - NCBI Bookshelf
    May 13, 2003 · Individuals with SMAD4-related JPS are more likely to have a personal or family history of upper GI polyps than individuals with a BMPR1A ...
  43. [43]
    The Gut Microbiome and Colorectal Cancer: An Integrative Review ...
    Feb 13, 2025 · This review appraises the roles of gut microbiota in promoting or preventing CRC. It also discusses the mechanistic interplay between microbiota composition.<|separator|>
  44. [44]
    High accuracy of a blood ctDNA-based multimodal test to detect ...
    Oct 5, 2023 · However, ctDNA detection may be limited by the small amount of DNA released by the tumor cells in early stages of CRC or precancerous lesions.
  45. [45]
  46. [46]
    Colorectal malignant polyps: a modern approach - PMC
    In this critical route to CRC, the adenoma-carcinoma sequence is accelerated, and sessile serrated lesions are the main precursor lesions [7]. CRC screening ...
  47. [47]
    Colonic Polyps and Polyposis Syndromes - DynaMed
    Feb 3, 2025 · Colon adenomas are found in 20%-53% of the United States population > 50 years old. The prevalence of advanced histology is reported to be 3.4%- ...
  48. [48]
    Hyperplastic polyp or sessile serrated lesion? The contribution of ...
    Dec 9, 2020 · The histological discrimination of hyperplastic polyps from sessile serrated lesions can be difficult. Sessile serrated lesions and hyperplastic ...
  49. [49]
    BSG/ACPGBI guidance on the management of colorectal polyps in ...
    Polyps should be assessed thoroughly prior to making a management decision, using existing guidelines for assessing the risk of the presence of cancer in polyp ...
  50. [50]
    Colon and Rectal Polyps | University of Michigan Health
    A polyp is a small growth of excess tissue that often grows on the lining of the large intestine, also known as the colon. Colon and rectal polyps occur in ...
  51. [51]
    Recommendation: Colorectal Cancer: Screening - uspstf
    May 18, 2021 · The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that ...Final recommendation statementScreening
  52. [52]
    Screening for Colorectal Cancer: US Preventive Services Task ...
    May 18, 2021 · The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit.
  53. [53]
    Multitarget Stool DNA Testing for Colorectal-Cancer Screening
    Mar 19, 2014 · The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced ...
  54. [54]
    Accuracy of CT Colonography for Detection of Large Adenomas and ...
    Sep 18, 2008 · The sensitivity of 0.90 (i.e., 90%) indicates that CT colonography failed to detect a lesion measuring 10 mm or more in diameter in 10% of ...Accuracy Of Ct Colonography... · Statistical Analysis · Per-Patient Assessment
  55. [55]
    CT Colonography for Colorectal Cancer Screening - AAFP
    Jan 1, 2021 · In a subsequent meta-analysis, the sensitivity of CT colonography for the detection of polyps 6 mm or larger was 73% to 98%; specificity ranged ...Accuracy · Benefit · Harms
  56. [56]
    Colon capsule endoscopy polyp detection rate vs colonoscopy ...
    Dec 18, 2024 · CCE showed higher sensitivity for polyp detection: 84% for polyps > 6 mm and 88% for polyps > 10 mm, with specificities of 64% and 95%, ...<|control11|><|separator|>
  57. [57]
    Integration of Artificial Intelligence-Enhanced Capsule Endoscopy in ...
    Jun 9, 2025 · This review focuses on the clinical applications of commercially available AI-powered capsule endoscopy systems, particularly for small bowel ...
  58. [58]
    Health disparities in colorectal cancer among racial and ethnic ...
    In 2010, CRC screening among adults >50 years old varied by ethnicity, with the lowest rate occurring in Hispanics (47%) when compared to nHw (62%) and AA (56%) ...
  59. [59]
    Racial and Ethnic Disparities in Colorectal Cancer Screening Pose ...
    Disparities in screening uptake across racial/ethnic minorities exist, with lower rates among blacks, Hispanics, Asians, Native Hawaiian/Pacific Islanders ...
  60. [60]
    Colonoscopy - StatPearls - NCBI Bookshelf - NIH
    Sep 14, 2025 · By facilitating the detection and removal of precancerous polyps, colonoscopy reduces progression to malignancy and improves survival outcomes.
  61. [61]
    Colonoscopy - Mayo Clinic
    Feb 28, 2024 · During the procedure ... During a colonoscopy, you'll wear a gown, but likely nothing else. Sedation or anesthesia is usually recommended. In most ...How You Prepare · What You Can Expect · ResultsMissing: endoscopic | Show results with:endoscopic
  62. [62]
    Colonoscopic polypectomy and associated techniques - PMC - NIH
    EMR involves submucosal injection (often of saline) creating a cushion for the polyp and then hot snaring the polyp either en bloc (all together) or piecemeal ...
  63. [63]
    [PDF] endoscopic-removal-of-colorectal-lesions-recommendations ... - ASGE
    2b: Non-pedunculated (10–19 mm) lesions. We suggest cold or hot snare polypectomy (with or without submucosal injection) to remove 10- to 19-mm non-pedunculated ...
  64. [64]
    Colorectal polyp classification and management of complex ... - NIH
    Sep 21, 2023 · We aimed to provide an overview of polyp classification techniques to help surgeons select the correct treatment algorithm for advanced colorectal lesions.Missing: structure | Show results with:structure
  65. [65]
    Narrow-band imaging observation of colorectal lesions using NICE ...
    NICE classification is very simple and based on 3 characteristics including: (1) lesion color; (2) microvascular architecture; and (3) surface pattern, which ...
  66. [66]
    a meta-analysis of diagnostic operating characteristics | Gut
    NBI diagnosis of colorectal polyps is highly accurate—the area under the HSROC curve exceeds 0.90. High-confidence predictions provide >90% sensitivity and NPV ...<|separator|>
  67. [67]
    Dye-based chromoendoscopy following polypectomy reduces ... - NIH
    Jan 8, 2020 · Conclusion Indigo carmine chromoendoscopy improves early detection of residual disease post polypectomy, reducing incomplete resection rates.
  68. [68]
    Cool it now: a new addition for resecting 10- to 14-mm polyps
    resection, a pathologically negative vertical margin, and no neoplastic tissue in 4-quadrant biopsy specimens taken around the resection margin. This leads to ...Missing: protocols | Show results with:protocols
  69. [69]
    How Long Do Biopsy Results Take?
    In general, the time frame for receiving biopsy results is usually between one to two weeks. However, it can be as short as a few days or, in some complex cases ...<|separator|>
  70. [70]
    European Society of Gastrointestinal Endoscopy (ESGE) Guideline
    Apr 26, 2024 · ESGE recommends cold snare polypectomy (CSP), to include a clear margin of normal tissue (1-2 mm) surrounding the polyp, for the removal of diminutive polyps ( ...
  71. [71]
    Endoscopic techniques for management of large colorectal polyps ...
    Jul 4, 2024 · Both hot (with electrocautery) and cold snare polypectomy techniques are effective in removing small colon polyps <10 mm in size, however ...
  72. [72]
    Clinical guidance on endoscopic management of colonic polyps in ...
    12. We recommend cold biopsy forceps for polyps 1–3 mm in size, while for polyps > 3 mm in size, cold snare polypectomy or jumbo forceps biopsy is preferred ( ...
  73. [73]
    Endoscopic mucosal resection for management of large colorectal ...
    Oct 18, 2018 · Large (greater than 2 cm) colorectal lesions can now be safely and effectively treated endoscopically, most commonly with endoscopic mucosal resection (EMR).
  74. [74]
    Use Both for the Best Outcomes | Annals of Internal Medicine
    Dec 12, 2023 · Endoscopic mucosal resection (EMR) has driven this change. Adverse events (AEs) are infrequent and recurrence rates of 1% to 2% are achievable ...
  75. [75]
    Colorectal endoscopic submucosal dissection: a systematic review ...
    Endoscopic en bloc and curative resection rates were 92 % (95 % CI, 90 – 94 %) and 86 % (95 % CI, 80 – 90 %), respectively. The rates of immediate and delayed ...
  76. [76]
    ESD vs EMR for Large Non-Pedunculated Colon Polyps
    Mar 19, 2024 · EMR (either en bloc or piecemeal) is an efficient, safe, and effective approach to remove large, non-pedunculated colorectal polyps.
  77. [77]
    Indication and results of endoscopic submucosal dissection for right ...
    ESD is related to a high percentage of en bloc resection and curative resection rates with an interval between 95.3% to 97.1% and 84.9% to 87.7 ...Introduction · Colorectal ESD: technique · Colorectal ESD: past, present... · Footnote
  78. [78]
    Endoscopic resection of large colorectal polyps: a narrative review ...
    Mar 30, 2022 · Key Content and Findings: Pedunculated polyps ≥10 mm are best removed by hot snare polypectomy (HSP) with ligation of the stalk if its thickness ...
  79. [79]
    Endoscopic Excision of Large Colorectal Polyps as a Viable ...
    Jun 20, 2011 · Although most large colorectal neoplasms require surgical resection, this study demonstrates that endoscopic excision of large colorectal polyps ...
  80. [80]
    Difficult colorectal polypectomy: Technical tips and recent advances
    May 7, 2023 · Advanced polypectomy techniques and skills are required for the resection of difficult colorectal polyps. Recent advancements in techniques ...
  81. [81]
    Management of Serrated Adenomas and Hyperplastic Polyps - PMC
    Hyperplastic polyps are nondysplastic, have little potential for malignant transformation,, and are considered distinct from adenomas. Recent evidence shows ...
  82. [82]
    Management of malignant colonic polyps - PMC - PubMed Central
    Endoscopic removal of these polyps can be achieved by conventional snare polypectomy or advanced endoscopic methods such as endoscopic mucosal resection (EMR) ...
  83. [83]
    Complication rates of colonic polypectomy in relation to polyp ... - NIH
    Fourteen patients or 24 (1.1%) polypectomies experienced complications. Two patients (0.09%) experienced perforation, 10 (0.47%) had bleeding and 3 (0.14%) had ...
  84. [84]
    Perforation and post-polypectomy bleeding complicating ... - NIH
    Vermeer et al reported rates confined to studies of screen-related morbidity, finding perforation at 0.07 per 1,000 (95 % CI 0.006, 0.17 per 1,000) and bleeding ...
  85. [85]
    Effectiveness of artificial intelligence-assisted colonoscopy in ... - NIH
    Oct 21, 2025 · Among different CADe models and advanced optical imaging techniques, ENDOANGEL model-assisted colonoscopy is the most effective method for ...
  86. [86]
    Research progress on the application of artificial intelligence in ...
    Oct 31, 2025 · The AI system achieved accuracy rates of 93.3%, 74.6%, and 55.1% for diminutive, small, and large polyps, respectively, comparable to those of ...
  87. [87]
    Recommendations for follow-up after colonoscopy and polypectomy
    Our aim was to review newly available evidence and update recommendations for follow-up after colonoscopy with or without polypectomy.
  88. [88]
    Adherence to Surveillance Guidelines after the Removal of ...
    Nov 15, 2021 · A recent meta-analysis of 16 studies reported a mean rate of surveillance interval adherence of 48.8%, suggesting that more than half of ...
  89. [89]
    Mechanisms of primary cancer prevention by butyrate and other ...
    Butyrate are recognised for their potential to act on secondary chemoprevention by slowing growth and activating apoptosis in colon cancer cells.
  90. [90]
    [PDF] Dietary and lifestyle patterns for cancer prevention:
    This report is from WCRF International's Global Cancer Update Programme (CUP Global): the world's largest source of scientific research on cancer prevention and ...
  91. [91]
    Association Between Consumption of Fruits and Vegetables... - LWW
    Thus, this meta-analysis suggested that fruits consumption have a significant protective effect on CRA risk, but not vegetables. Moreover, we recommend ...
  92. [92]
    Red Meat and Colorectal Cancer - PMC - NIH
    If average red meat intake is reduced to 70 g/week, CRC risk hypothetically decreases by 7-24%. From Karolinska Institute, Sweden, Larsson and Wolk's meta- ...
  93. [93]
    systematic review and meta-analysis of observational studies
    For instance, moderate intensity activity for at least 150 min each week ... Leisure and occupational physical activity and risk of colorectal adenomatous polyps.Methods · Results · Discussion<|separator|>
  94. [94]
    Weight loss reduces the risk of growths linked to colorectal cancer
    Feb 1, 2022 · Overweight and obese people who lose weight may reduce their chances of later developing colorectal adenoma – a type of benign growth or polyp in the colon or ...
  95. [95]
    Moderate Alcohol Consumption is Protective Against Colorectal ...
    Consumption of less than seven alcohol drinks per week does not increase the risk of having a colorectal adenoma. We found evidence in this study that moderate ...
  96. [96]
    Colorectal Cancer Guideline | How Often to Have Screening Tests
    Jan 29, 2024 · The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45.
  97. [97]
    [PDF] Uncovering Inequalities – Colorectal Cancer Screening in Europe
    Organised, population-based screening for colorectal cancer leads to substantial decreases in cancer incidence and mortality.
  98. [98]
    Fecal Immunochemical Test Screening and Colorectal Cancer Death
    Jul 19, 2024 · FIT screening programs have reported reduced CRC incidence and mortality, but further evidence on effectiveness is limited. Observational ...
  99. [99]
    Low-dose aspirin can prevent bowel cancer in people with Lynch ...
    Jun 24, 2025 · CaPP3's results show that taking as little as 75 to 100mg of aspirin each day can halve the risk of bowel cancer in people with Lynch syndrome.
  100. [100]
  101. [101]
    Recommendation: Aspirin Use to Prevent Cardiovascular Disease
    Apr 26, 2022 · The evidence is unclear whether aspirin use reduces the risk of colorectal cancer incidence or mortality.
  102. [102]
    Treatment of Colonic and Rectal Adenomas with Sulindac in ...
    May 6, 1993 · Sulindac reduces the number and size of colorectal adenomas in patients with familial adenomatous polyposis, but its effect is incomplete.
  103. [103]
    Chemoprevention in familial adenomatous polyposis - PMC - NIH
    In a treatment span of 9 months, 150 mg of sulindac twice a day showed statistically significant reduction in polyp count and diameter compared to placebo.
  104. [104]
    Reduced Risk of Colorectal Cancer With Metformin Therapy in ... - NIH
    From observational studies, metformin therapy appears to be associated with a significantly lower risk of colorectal cancer in patients with type 2 diabetes.
  105. [105]
    Metformin Use and Risk of Colorectal Adenoma after Polypectomy in ...
    We found that, in patients with type 2 diabetes, metformin use was associated with a lower risk of colorectal adenoma recurrence when compared with no diabetes ...<|separator|>
  106. [106]
    Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer | NEJM
    ### Summary of VITAL Trial Vitamin D and Colorectal Adenomas Results
  107. [107]
    Refining colorectal cancer screening strategies using polygenic risk ...
    Jan 27, 2025 · Three models were assessed: a polygenic risk score (PRS)-only model, a classical risk factors (RF)-only model, and a combined (PRS + RF) model.
  108. [108]
    Genome-wide Modeling of Polygenic Risk Score in Colorectal ...
    Based on the LDpred-derived PRS, we are able to identify 30% of individuals without a family history as having risk for CRC similar to those with a family ...<|control11|><|separator|>